Modakafusp alfa

DB16399InvestigationalProtein Based Therapies

Modakafusp alfa is under investigation in clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)).

Mechanism: Pharmacologically active on ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 and Interferon alpha/beta receptor (IFNAR)
Curator reviewed
Also known as: Anti-CD38-targeted IGG4-attenuated IFNA TAK-573
Code names: TAK-573 · TEV-48573

Resolves to

Compound

UNIITN8CEX4UT2

Targets

P28907CD38

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Modakafusp alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account